文献速递神经肿瘤

声动力疗法对恶性胶质母细胞瘤杀伤作用研究

Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors.
PubMed 文献 · J Neurooncol · 2020-05-02

研究在C6大鼠与U87人胶质母细胞瘤细胞中评估5-ALA联合高频聚焦超声的声动力疗法(SDT)。SDT组细胞活力较对照下降47%,caspase-3诱导增加278%,凋亡染色阳性率显著高于单用5-ALA或FUS,U87细胞呈类似反应。

要点

  • SDT联合5-ALA与FUS较单用任一手段更显著降低胶质母细胞瘤细胞活力。
  • SDT组caspase-3诱导与凋亡染色阳性率均显著升高,提示凋亡参与杀伤。
  • 该策略将两种已获FDA批准的技术联用,但尚属体外细胞研究。

核心结论

  • 声动力疗法较单用5-ALA或聚焦超声引起更明显的胶质母细胞瘤细胞死亡。

研究设计与样本

  • 体外研究,使用大鼠C6与人U87两种胶质母细胞瘤细胞系,设5-ALA、FUS、SDT及对照四组。

主要发现

  • C6细胞MTT法示5-ALA、FUS、SDT组细胞活力较对照分别下降5%、16%、47%(p < 0.05)。
  • C6细胞caspase-3诱导较对照分别增加109%、110%、278%(p < 0.05)。
  • C6细胞caspase-3染色阳性率对照组、5-ALA、FUS、SDT组分别为2.1%、6.7%、11.2%、39.8%。
  • C6细胞Parp-1染色阳性率对照组、5-ALA、FUS、SDT组分别为1.9%、6.5%、9.0%、37.8%。
  • U87细胞对上述处理呈类似反应。

临床怎么用

  • 目前仅为细胞水平证据,尚不能用于临床决策,需进一步体内与临床研究验证。

局限性

  • 研究限于两种细胞系的体外实验,未报告动物模型或临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glioblastoma is the most common primary brain tumor; survival is typically 12-18 months after diagnosis. We sought to study the effects of sonodynamic therapy (SDT) using 5-Aminolevulinic acid hydrochloride (5-ALA) and high frequency focused ultrasound (FUS) on 2 glioblastoma cell lines. PROCEDURE: Rat C6 and human U87 glioblastoma cells were studied under the following conditions: 1 mM 5-ALA (5-ALA); focused ultrasound (FUS); 5-ALA and focused ultrasound (SDT); control. Studied responses included cell viability using an MTT assay, microscopic changes using phase contract microscopy, apoptotic induction through a caspase-3 assay, and apoptosis staining to quantify cell death. RESULTS: SDT led to a marked decrease in cell extension and reduction in cell size. For C6, the MTT assay showed reductions in cell viability for 5-ALA, FUS, and SDT groups of 5%, 16%, and 47%, respectively compared to control (p < 0.05). Caspase 3 induction in C6 cells relative to control showed increases of 109%, 110%, and 278% for 5-ALA, FUS, and SDT groups, respectively (p < 0.05). For the C6 cells, caspase 3 staining positivity was 2.1%, 6.7%, 11.2%, and 39.8% for control, 5-ALA, FUS, and SDT groups, respectively. C6 Parp-1 staining positivity was 1.9%, 6.5%, 9.0%, and 37.8% for control, 5-ALA, FUS, and SDT groups, respectively. U87 cells showed similar responses to the treatments. CONCLUSIONS: Sonodynamic therapy resulted in appreciable glioblastoma cell death as compared to 5-ALA or FUS alone. The approach couples two already FDA approved techniques in a novel way to treat the most aggressive and malignant of brain tumors. Further study of this promising technique is planned.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Sheehan K, Sheehan D, Sulaiman M, et al. Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors. J Neurooncol. 2020. PMID: 32361864. doi:10.1007/s11060-020-03504-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。